Sab Biotherapeutics Stock Probability Of Bankruptcy
| SABS Stock | USD 2.94 0.10 3.52% |
SAB | Probability Of Bankruptcy |
SAB Biotherapeutics Company probability of financial unrest Analysis
SAB Biotherapeutics' Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
More About Probability Of Bankruptcy | All Equity Analysis
Probability Of Bankruptcy | = | Normalized | | Z-Score |
Current SAB Biotherapeutics Probability Of Bankruptcy | Less than 46% |
Most of SAB Biotherapeutics' fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, SAB Biotherapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Our calculation of SAB Biotherapeutics probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting SAB Biotherapeutics odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of SAB Biotherapeutics financial health.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of SAB Biotherapeutics. If investors know SAB will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about SAB Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.60) | Earnings Share (6.72) | Revenue Per Share 0.396 | Quarterly Revenue Growth 0.625 | Return On Assets (0.46) |
The market value of SAB Biotherapeutics is measured differently than its book value, which is the value of SAB that is recorded on the company's balance sheet. Investors also form their own opinion of SAB Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is SAB Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because SAB Biotherapeutics' market value can be influenced by many factors that don't directly affect SAB Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between SAB Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if SAB Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, SAB Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
SAB Probability Of Bankruptcy Driver Correlations
Understanding the fundamental principles of building solid financial models for SAB Biotherapeutics is extremely important. It helps to project a fair market value of SAB Stock properly, considering its historical fundamentals such as Probability Of Bankruptcy. Since SAB Biotherapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of SAB Biotherapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of SAB Biotherapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
| Competition |
Based on the latest financial disclosure, SAB Biotherapeutics has a Probability Of Bankruptcy of 46.0%. This is 6.26% higher than that of the Biotechnology sector and 16.12% lower than that of the Health Care industry. The probability of bankruptcy for all United States stocks is 15.49% lower than that of the firm.
SAB Probability Of Bankruptcy Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses SAB Biotherapeutics' direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of SAB Biotherapeutics could also be used in its relative valuation, which is a method of valuing SAB Biotherapeutics by comparing valuation metrics of similar companies.SAB Biotherapeutics is currently under evaluation in probability of bankruptcy category among its peers.
SAB Biotherapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, SAB Biotherapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to SAB Biotherapeutics' managers, analysts, and investors.Environmental | Governance | Social |
SAB Fundamentals
| Return On Equity | -1.03 | ||||
| Return On Asset | -0.46 | ||||
| Operating Margin | (12.06) % | ||||
| Current Valuation | (11.44 M) | ||||
| Shares Outstanding | 9.23 M | ||||
| Shares Owned By Insiders | 19.15 % | ||||
| Shares Owned By Institutions | 36.91 % | ||||
| Number Of Shares Shorted | 22.46 K | ||||
| Price To Book | 0.75 X | ||||
| Price To Sales | 19.26 X | ||||
| Revenue | 2.24 M | ||||
| Gross Profit | (12.53 M) | ||||
| EBITDA | (34.33 M) | ||||
| Net Income | (42.19 M) | ||||
| Cash And Equivalents | 16.62 M | ||||
| Cash Per Share | 0.39 X | ||||
| Total Debt | 5.91 M | ||||
| Debt To Equity | 0.16 % | ||||
| Current Ratio | 1.72 X | ||||
| Book Value Per Share | 5.72 X | ||||
| Cash Flow From Operations | (25.12 M) | ||||
| Short Ratio | 4.47 X | ||||
| Earnings Per Share | (6.72) X | ||||
| Target Price | 15.5 | ||||
| Number Of Employees | 57 | ||||
| Beta | 0.64 | ||||
| Market Capitalization | 27.17 M | ||||
| Total Asset | 83.94 M | ||||
| Retained Earnings | (90.06 M) | ||||
| Working Capital | 48.09 M | ||||
| Net Asset | 83.94 M |
About SAB Biotherapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze SAB Biotherapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of SAB Biotherapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of SAB Biotherapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with SAB Biotherapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if SAB Biotherapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in SAB Biotherapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with SAB Stock
Moving against SAB Stock
| 0.82 | AZN | AstraZeneca PLC ADR | PairCorr |
| 0.79 | GNFT | Genfit | PairCorr |
| 0.7 | LLY | Eli Lilly | PairCorr |
| 0.66 | VALN | Valneva SE ADR | PairCorr |
| 0.64 | DYAI | Dyadic International | PairCorr |
The ability to find closely correlated positions to SAB Biotherapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace SAB Biotherapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back SAB Biotherapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling SAB Biotherapeutics to buy it.
The correlation of SAB Biotherapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as SAB Biotherapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if SAB Biotherapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for SAB Biotherapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for SAB Stock Analysis
When running SAB Biotherapeutics' price analysis, check to measure SAB Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SAB Biotherapeutics is operating at the current time. Most of SAB Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of SAB Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SAB Biotherapeutics' price. Additionally, you may evaluate how the addition of SAB Biotherapeutics to your portfolios can decrease your overall portfolio volatility.